Increased miR-7641 Levels in Peritoneal Hyalinizing Vasculopathy in Long-Term Peritoneal Dialysis Patients

Raquel Díaz1,2, Pilar Sandoval3, Raul R Rodrigues-Diez2,4

  • 1Research Institute of La Paz (IdiPAZ), University Hospital La Paz, 28046 Madrid, Spain.

Insights

Peritoneal hyalinizing vasculopathy (PHV) in peritoneal dialysis (PD) patients may stem from endothelial-to-mesenchymal transition (EndMT) driven by glucose degradation products (GDPs). Lower PHV rates were observed with protective factors like ACE inhibitors and statins.

Area of Science:

  • Nephrology
  • Vascular Biology
  • Molecular Biology

Background:

  • Peritoneal hyalinizing vasculopathy (PHV) is a key feature of encapsulating peritoneal sclerosis in long-term peritoneal dialysis (PD) patients.
  • The underlying mechanisms driving PHV development are not well understood.

Purpose of the Study:

  • To investigate the pathological mechanisms of PHV in PD patients.
  • To identify potential protective factors against PHV development.

Main Methods:

  • Cross-sectional study of 100 PD patient peritoneal biopsies.
  • Clinical data collection and immunohistochemical evaluation of lesions.
  • MicroRNA (miRNA)-sequencing analysis in selected biopsies.

Main Results:

  • PHV was present in 15% of patients, with lower prevalence linked to low glucose degradation products (GDPs), ACE inhibitors, statins, and residual renal function.
  • PHV biopsies showed endothelial marker loss, mesenchymal protein induction, collagen IV accumulation, and basement membrane reduplication.
  • Evidence of endothelial-to-mesenchymal transition (EndMT) and activated TGF-β1/Smad3 signaling was observed.
  • Higher miR-7641 levels were found in severe PHV cases.

Conclusions:

  • Glucose degradation products (GDPs) may induce miRNA deregulation and EndMT in peritoneal submesothelial vessels, contributing to PHV.
  • ACE inhibitors, statins, and residual renal function may offer protection against PHV.

Related Concept Videos

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
283
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
860
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
386
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
448
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
417
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
1.4K